Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

NCT02194595 on ClinicalTrials.gov · last registry update 2022-04-11

A small phase 3 — 105 participants, against a typical 424. The sponsor logged completion for December 2021. Primary outcome, as filed: Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Mount Sinai Hospital, Canada
Sponsor type: Other
Enrollment: 105
Started: 2014-09
Primary completion: 2021-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean beta-cell function over the 8-week treatment period, measured using the Insulin Secretion-Sensitivity Index-2 (ISSI-2)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.